FRANKFURT (Reuters) – Bayer’s
Baumann, whose contract would have expired in April next year, was given a three-year extension by the German drugmaker’s supervisory board, it said in a statement late on Thursday.
(Reporting by Ludwig Burger; Editing by Sandra Maler)